RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
TFA Therapeutics, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$9.18+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
$0.00 (0.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
TFA Therapeutics, Inc. saw revenue fall 0.6% to $1.25M over fiscal 2025.
Revenue
$1.25M
-0.6% vs. a year earlier
Operating income
-$141.13K
FY2025
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.25M
- Net income
- -$154.82K
- EPS, diluted
- $0.00
Six years at a glance
Fiscal years 2020 to 2025, USD
Revenue
$1.25M-0.6% YoY
Gross profit
$760.74K-16.1% YoY
Operating income
-$141.13K
Net income
-$154.82K
EPS, diluted
$0.00
Free cash flow
–
Reported period